Catalio Capital Management’s Dianthus Therapeutics DNTH Stock Holding History

Catalio Capital Management’s Portfolio DNTH Stock Details DNTH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3.21M	Sell	32,941 -527,367	-94%	-$46.1M	0.6%	32
2026 Q1	$47M	Sell	560,308 -93,264	-14%	-$5.4M	9.82%	1
2025 Q4	$26.9M	Sell	653,572 -14,043	-2%	-$544K	4.76%	6
2025 Q3	$26.3M	Sell	667,615 -78,912	-11%	-$2.02M	4.86%	7
2025 Q2	$13.9M	Sell	746,527 -16,944	-2%	-$318K	2.92%	15
2025 Q1	$13.8M	Hold	763,471	–	–	3.37%	12
2024 Q4	$16.6M	Buy	+763,471	New	+$19.6M	3.64%	15

Other funds holding DNTH

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

APM

Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return

OCA

Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return

Catalio Capital Management's DNTH Position: Q2 2026 in Review

Catalio Capital Management reduced its Dianthus Therapeutics (DNTH) stake by 94% in Q2 2026, selling an estimated $46.1M and leaving 32,941 shares worth $3.21M. The position accounts for 0.6% of the portfolio, ranked #32.

Catalio Capital Management first reported a position in DNTH in Q4 2024 and has held it in 7 quarters since. The position peaked at $47M in Q1 2026. 270 funds tracked by Wall St. Rank hold DNTH as of Q2 2026.

Catalio Capital Management held 32,941 shares of Dianthus Therapeutics worth $3.21M as of Q2 2026.
Catalio Capital Management sold 527,367 Dianthus Therapeutics shares in Q2 2026, an estimated $46.1M.
Dianthus Therapeutics made up 0.6% of Catalio Capital Management's portfolio in Q2 2026, its #32 holding.
Catalio Capital Management first reported a position in Dianthus Therapeutics in Q4 2024 and has held it in 7 quarters since.
Catalio Capital Management's Dianthus Therapeutics position peaked at $47M in Q1 2026.
270 funds tracked by Wall St. Rank held Dianthus Therapeutics as of Q2 2026.

Based on Catalio Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.